Table 1

In vivo studies of NBL

Tumor size (cm3)Analysis of slopea
Cell lineDay of analysisCompoundControlCompoundControl
A. Neuroblastoma therapeutic studiesb
IMR-5121.96 ± 0.35 (n = 5)3.91 ± 1.22 (n = 5)0.17 ± 0.051 (n = 5)0.28 ± 0.109 (n = 5)
P = 0.025P = 0.024
CHP 134151.9 ± 0.75 (n = 4)4.5 ± 0.98 (n = 3)0.151 ± 0.055 (n = 6)0.299 ± 0.068 (n = 5)
P = 0.034P = 0.12
NBL-S170.94 ± 0.24 (n = 5)5.2 ± 2.46 (n = 4)0.15 ± 0.034 (n = 5)0.264 ± 0.014 (n = 4)
P = 0.016P = 0.12
B. Neuroblastoma prevention studiesc
IMR-5271.3 ± 1.63 (n = 7)2.7 ± 1.55 (n = 6)0.118 ± 0.036 (n = 7)0.188 ± 0.041 (n = 6)
P = 0.062P = 0.073
CHP 134 (combined)See text0.064 ± (n = 6)0.122 ± (n = 6)
P = 0.058
CHP 134 (early)29See text0.148 ± 0.013 (n = 3)0.169 ± 0.01 (n = 3)
P = 0.28
CHP 134 (late)58See text0.022 ± 0.011 (n = 3)0.140 ± 0.009 (n = 3)
P = 0.049
  • a Figures given for the average daily growth rate.

  • b Treatment started after tumors measured >0.24 g.

  • c Treatment commenced prior to tumor appearance.